Search
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigational[L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.
Pyrithione
go.drugbank.com/drugs/DB06815ApprovedInvestigationalWhile its use has been approved in the early 1960's by the FDA [A32163], safety and effectiveness of pyrithione zinc has been reported for decades.
Clobazam
go.drugbank.com/drugs/DB00349ApprovedIllicitInvestigational[A521,A522] In October 21, 2011, the FDA approved clobazam as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children aged two years and older.
Neomycin
go.drugbank.com/drugs/DB00994ApprovedInvestigationalVet approvedNeomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framyce...
Mixtures: DAYMARK FAK-35 First AidPemivibart
go.drugbank.com/drugs/DB18720Investigational[L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
Icotinib
go.drugbank.com/drugs/DB11737Investigationalepidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIvacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012...
Invert sugar
go.drugbank.com/drugs/DB09344Experimental[A32124] Invert sugar is FDA approved since 1988 as a safe substance (GRAS).